Policy

Biosimilars Gain Market Share and Advocates Get Aboard

August 15th 2020

By Skylar Jeremias

There has been an outpouring of advocacy tugging biosimilars into the marketplace, and market share of these lower-cost drugs has increased.

Automatic Substitution Pays Off for Compass Oncology West

August 14th 2020

By Skylar Jeremias

Allowing pharmacists to independently fill prescriptions with biosimilars can offer community oncology practices a way to cut costs and increase access to cancer care for patients, according to Lucy Langer, MD.

Pfizer Expert Urges Employers to Get Proactive on Biosimilars

August 13th 2020

By Tony Hagen

Defining biosimilar use in the United States as "sluggish," Juliana Reed, MS, said employers have to get involved.

Part 2: Nancy Globus on Whether or Not Biosimilar Naming Causes Confusion

August 13th 2020

Nancy J. Globus, PharmD, vice president of Regulatory Affairs at the Accreditation Council for Medical Affairs (ACMA), discusses the truth behind 4-letter suffixes and product confusion among physicians and pharmacists.

Disney Official, Others Talk About Switch to Biosimilars

August 13th 2020

By Tony Hagen

Dismayed at the low biosimilar uptake and the lost savings, large employers are taking matters into their own hands.

At University of Missouri Health Care, Biosimilars Are Transformative but Somewhat Restricted

August 12th 2020

By Tony Hagen

Pharmacy experts discuss their level of confidence with biosimilars and some of the hurdles that stand in the way of optimizing these lower-cost medicines.

Study: How Out-of-Pocket Caps Affect Payer Policy

August 7th 2020

By Tony Hagen

Investigators set out to learn whether the imposition of out-of-pocket spending caps on specialty drugs would unleash a wave of drug spending and prompt payer policy change.

ASCO Study: Mandatory Drug Licensing Can Bridge Care Divide

August 5th 2020

By Skylar Jeremias

Biosimilars have improved access to health care in India, but many effective new drugs are high priced and patented, and authors of a new study recommend interventions to make these available, too.

Oubre: The Practice Perspective on Biosimilar Contracts

August 4th 2020

By Tony Hagen

An oncology practice administrator describes the careful calculus involved in balancing patient needs with the business side of biosimilars and cancer care.

Kashyap Patel, MD: A Champion for Biosimilars Uptake and Education

July 30th 2020

By Skylar Jeremias

The Center for Biosimilars® spoke with Kashyap B. Patel, MD, about his work in promoting biosimilar uptake and his upcoming book on the importance of living life and not fearing death.